KRAS and juvenile myelomonocytic leukemia: Our findings support the concept that oncogenic KRAS does not only act via its oncogenic driver function but also enhances activation of the NLRP3/IL-1β axis, which explains the clinical features of JMML and CMML patients suffering from inflammation-related symptoms.